Release Details

Cytori Reports Q1 2019 Business and Financial Results

May 14, 2019

SAN DIEGO, May 14, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced Q1 2019 financial results and provided updates on corporate activities. 

Q1 2019 net loss was $3.2 million, or $0.18 per share. Operating cash burn for Q1 was approximately $3.3 million. Cytori ended Q1 with approximately $3.9 million of cash and cash equivalents.

Cytori is developing two clinical stage chemotherapy drugs. ATI-0918, a generic version of pegylated liposomal doxorubicin hydrochloride, is the lead product candidate. The Company plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) next year based on a successful bioequivalence study completed against the European reference drug. The Company is in the process of completing manufacturing-related activities to support the MAA and is evaluating commercial partners for ATI-0918 with a focus on Europe, which has a current estimated market size of over $120 million.

Cytori is also developing ATI-1123, a patented, albumin-stabilized pegylated liposomal docetaxel. The Company recently received an orphan drug designation from the U.S. FDA for small cell lung cancer and is seeking FDA’s 505(b)(2) new drug application (NDA) and Accelerated Approval pathway.

“The Company’s recent divestiture of its cell therapy businesses allows us to fundamentally reposition and refocus of the Company around our nanotechnology and oncology drug development,” said Dr. Marc Hedrick, President and Chief Executive Officer of Cytori. We intend to begin communicating our plan later in Q2.

Q1 2019 Financial Performance

  • Q1 2019 operating cash burn was $3.3 million, compared to $4.1 million for Q1 2018.
  • Q1 2019 product revenues were $0.7 million, compared to $0.7 million for Q1 2018.
  • Q1 2019 contract revenues were $0.7 million, compared to $0.9 million for Q1 2018.
  • Q1 2019 Celution® consumable utilization grew by approximately 20% as compared to Q1 2018.
  • Cash and debt principal balances at March 31, 2019 were approximately $3.9 million and $13.0 million, respectively.
  • Q1 2019 net loss was $3.2 million or $0.18 per share, compared to a net loss of $4.4 million or $0.73 per share for Q1 2018.

About Cytori

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs.  Cytori is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents or other drugs which may enable the effective delivery of the agents to target sites while reducing systemic toxicity and improving pharamacokinetics.  Our pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors.  For more information, visit

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements about our anticipated expenditures, including research and development, sales and marketing, and general and administrative expenses; the potential size of the market for our products; future development and/or expansion of our products and therapies in our markets, our ability to generate  product or development revenues and the sources of such revenues; our ability to effectively manage our gross profit margins; our ability to obtain and maintain regulatory approvals; expectations as to our future performance; portions of the “Liquidity and Capital Resources” section of this report, including our potential need for additional financing and the availability thereof; our ability to continue as a going concern; our ability to remain listed on the Nasdaq Capital Market; our ability to repay or refinance some or all of our outstanding indebtedness and our ability to raise capital in the future; and the potential enhancement of our cash position through development, marketing, and licensing arrangements.   Our actual results will likely differ, perhaps materially, from those anticipated in these forward-looking statements as a result of various factors, including: the early stage of our product candidates and therapies, the results of our research and development activities, including uncertainties relating to the clinical trials of our product candidates and therapies; our need and ability to raise additional cash, the outcome of our partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to us, market conditions, product performance, potential litigation, and competition within the regenerative medicine field, to name a few. The forward-looking statements included in this report are subject to a number of additional material risks and uncertainties, including but not limited to the risks described under the “Risk Factors” in the Cytori's Securities and Exchange Commission Filings, included in the Company’s annual and quarterly reports.

There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. Federal securities laws to do so.


(in thousands, except share and par value data)

    As of March 31,
    As of December 31,
Current assets:                
Cash and cash equivalents   $ 3,872     $ 5,261  
Accounts receivable, net of reserves of $185 in 2019 and $185 in 2018     455       286  
Restricted cash     40       40  
Inventories, net     3,003       2,947  
Other current assets     1,092       1,114  
Total current assets     8,462       9,648  
Property and equipment, net     2,607       2,559  
Operating lease right-of-use assets     2,153        
Other assets     1,827       1,905  
Intangibles, net     5,645       5,957  
Goodwill     3,922       3,922  
Total assets   $ 24,616     $ 23,991  
Liabilities and Stockholders’ Equity                
Current liabilities:                
Accounts payable and accrued expenses   $ 3,224     $ 3,357  
Operating lease liability     700        
Term loan obligations, net of discount     14,371       14,202  
Total current liabilities     18,295       17,559  
Deferred revenues     142       167  
Other noncurrent liabilities     98       124  
Noncurrent operating lease liability     1,518        
Warrant liability     706       916  
Total liabilities     20,759       18,766  
Commitments and contingencies                
Stockholders’ equity:                
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 30,233 shares
  issued; 4,540 and 4,606 shares outstanding in 2019 and 2018, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 21,905,795 and
  14,830,414 shares issued and outstanding in 2019 and 2018, respectively
    22       15  
Additional paid-in capital     420,290       418,375  
Accumulated other comprehensive income     1,078       1,218  
Accumulated deficit     (417,533 )     (414,383 )
Total stockholders’ equity     3,857       5,225  
Total liabilities and stockholders’ equity   $ 24,616     $ 23,991  


(in thousands, except share and per share data)

    For the Three Months Ended March 31,  
    2019     2018  
Product revenues   $ 703     $ 731  
Cost of product revenues     (353 )     (273 )
Amortization of intangible assets     (306 )     (306 )
Gross profit     44       152  
Development revenues:                
Government contracts and other     737       917  
      737       917  
Operating expenses:                
Research and development     1,846       2,499  
Sales and marketing     428       678  
General and administrative     1,508       2,244  
Total operating expenses     3,782       5,421  
Operating loss     (3,001 )     (4,352 )
Other income (expense):                
Interest income     7       14  
Interest expense     (515 )     (423 )
Other income (expense), net     149       352  
Change in fair value of warrants     210        
 Total other expense     (149 )     (57 )
Net loss   $ (3,150 )   $ (4,409 )
Basic and diluted net loss per share attributable to common stockholders   $ (0.18 )   $ (0.73 )
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders     17,657,108       6,017,791  
Comprehensive loss:                
Net loss   $ (3,150 )   $ (4,409 )
Other comprehensive loss – foreign currency translation adjustments     (140 )     (281 )
Comprehensive loss   $ (3,290 )   $ (4,690 )


(in thousands)

    For the Three Months Ended March 31,
    2019     2018  
Cash flows from operating activities:              
Net loss   $ (3,150 )   $ (4,409 )
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization     443       497  
Amortization of deferred financing costs and debt discount     168       105  
Provision for excess inventory           326  
Change in fair value of warrants     (210 )      
Share-based compensation expense     49       143  
Loss on asset disposal           22  
Increases (decreases) in cash caused by changes in operating assets and liabilities:              
Accounts receivable     (212 )     (747 )
Inventories     16       141  
Other current assets     16       301  
Other assets     1       (24 )
Accounts payable and accrued expenses     (405 )     (556 )
Deferred revenues     (25 )     84  
Other long-term liabilities     39       (2 )
   Net cash used in operating activities     (3,270 )     (4,119 )
Cash flows from investing activities:              
Purchases of property and equipment     (6 )     (53 )
   Net cash used in investing activities     (6 )     (53 )
Cash flows from financing activities:              
Payment of financing lease liability     (28 )      
Proceeds from sale of common stock, net     1,919       (150 )
   Net cash provided by (used in) financing activities     1,891       (150 )
   Effect of exchange rate changes on cash and cash equivalents     (4 )     39  
   Net decrease in cash and cash equivalents     (1,389 )     (4,283 )
Cash, cash equivalents, and restricted cash at beginning of period     5,301       10,225  
Cash, cash equivalents, and restricted cash at end of period   $ 3,912     $ 5,942  



Gary Titus


Source: Cytori Therapeutics Inc.